HRP20231652T1 - Peptidi za primjenu u liječenju oralnog mukozitisa - Google Patents
Peptidi za primjenu u liječenju oralnog mukozitisa Download PDFInfo
- Publication number
- HRP20231652T1 HRP20231652T1 HRP20231652TT HRP20231652T HRP20231652T1 HR P20231652 T1 HRP20231652 T1 HR P20231652T1 HR P20231652T T HRP20231652T T HR P20231652TT HR P20231652 T HRP20231652 T HR P20231652T HR P20231652 T1 HRP20231652 T1 HR P20231652T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- use according
- treatment
- oral mucositis
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 12
- 208000003265 stomatitis Diseases 0.000 title claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 150000001408 amides Chemical class 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Peptid za primjenu u liječenju oralnog mukozitisa kod subjekta koji je bio izložen oštećujućoj količini zračenja ili kemoterapijskih agenasa, pri čemu peptid je peptid koji sadrži aminokiselinsku sekvencu bilo koje od SEK ID BR: 5, 10, 24, 27, 28, 31, 34, 63 i 90 ili farmaceutsku sol, ester ili amid istog i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
2. Peptid za primjenu prema patentnom zahtjevu 1, pri čemu peptid je SEK ID BR: 5 ili farmaceutska sol, ester, ili amid istog i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
3. Peptid za primjenu prema patentnom zahtjevu 1, pri čemu se peptid administrira oralno, supkutano, intramuskularno, intravenozno, transdermalno, intranazalno, plućnom administracijom, ili pomoću osmotske pumpe.
4. Peptid za primjenu prema patentnom zahtjevu 2, pri čemu efektivna količina peptida je najmanje 1.5 mg/kg.
5. Peptid za primjenu prema patentnom zahtjevu 2, pri čemu se peptid administrira pacijentu svakog trećeg dana tokom zračenja ili administriranja kemoterapijskog agensa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877767P | 2013-09-13 | 2013-09-13 | |
| PCT/US2014/050516 WO2015038264A1 (en) | 2013-09-13 | 2014-08-11 | Novel peptides and analogs for use in the treatment of oral mucositis |
| EP14844276.7A EP3044229B1 (en) | 2013-09-13 | 2014-08-11 | Peptides for use in the treatment of oral mucositis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231652T1 true HRP20231652T1 (hr) | 2024-05-10 |
Family
ID=52666140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231652TT HRP20231652T1 (hr) | 2013-09-13 | 2014-08-11 | Peptidi za primjenu u liječenju oralnog mukozitisa |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9850279B2 (hr) |
| EP (1) | EP3044229B1 (hr) |
| JP (2) | JP6645968B2 (hr) |
| KR (3) | KR102483333B1 (hr) |
| CN (1) | CN105722852B (hr) |
| AU (3) | AU2014318247B2 (hr) |
| BR (1) | BR112016005557B1 (hr) |
| CA (1) | CA2923553C (hr) |
| DK (1) | DK3044229T3 (hr) |
| ES (1) | ES2965906T3 (hr) |
| FI (1) | FI3044229T3 (hr) |
| HK (1) | HK1221960A1 (hr) |
| HR (1) | HRP20231652T1 (hr) |
| HU (1) | HUE066502T2 (hr) |
| IL (1) | IL244573B (hr) |
| LT (1) | LT3044229T (hr) |
| MX (1) | MX2016003092A (hr) |
| MY (1) | MY177930A (hr) |
| NZ (2) | NZ718534A (hr) |
| PL (1) | PL3044229T3 (hr) |
| PT (1) | PT3044229T (hr) |
| RU (1) | RU2668963C2 (hr) |
| SG (1) | SG11201601891XA (hr) |
| WO (1) | WO2015038264A1 (hr) |
| ZA (2) | ZA201601967B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9808438B2 (en) * | 2015-11-09 | 2017-11-07 | Enzychem Lifesciences Corporation | Method for treating mucositis |
| GB201711183D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Antimicrobial or wound care materials, devices and uses |
| US20200108098A1 (en) * | 2018-02-23 | 2020-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
| KR102192471B1 (ko) * | 2019-10-18 | 2020-12-17 | 주식회사 인코스팜 | 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물 |
| EP4221737A1 (en) | 2020-09-30 | 2023-08-09 | Biotempt B.V. | Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability |
| CA3227834A1 (en) | 2021-08-30 | 2023-03-09 | Dhananjay Sathe | Protein compositions for the treatment of inflammatory diseases |
| CN115944708A (zh) * | 2021-12-28 | 2023-04-11 | 四川好医生攀西药业有限责任公司 | 三肽在制备治疗和/或预防黏膜或皮肤损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2701281B2 (ja) * | 1988-01-22 | 1998-01-21 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| US20030162706A1 (en) * | 2002-02-08 | 2003-08-28 | The Procter & Gamble Company | Angiogenesis modulating proteins |
| RU2004128444A (ru) | 2002-02-26 | 2005-06-10 | Сэнгстат Медикал Корпорейшн (Us) | Способы и композиции для лечения желудочно-кишечной токсичности, вызванной цитодеструктивной терапией |
| CN1269837C (zh) * | 2002-09-02 | 2006-08-16 | 上海高科联合生物技术研发有限公司 | 一组合成抗菌肽 |
| PL2236608T3 (pl) * | 2005-10-04 | 2017-06-30 | Soligenix, Inc. | Nowe peptydy do leczenia i profilaktyki zaburzeń immuno-zależnych w tym do leczenia i profilaktyki zakażenia przez modulację odporności wrodzonej |
| WO2008040111A1 (en) * | 2006-10-04 | 2008-04-10 | Inimex Pharmaceuticals Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| WO2008143679A2 (en) * | 2006-06-01 | 2008-11-27 | Verenium Corporation | Nucleic acids and proteins and methods for making and using them |
| CN101578368A (zh) * | 2006-10-04 | 2009-11-11 | 伊尼梅克斯制药公司 | 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽 |
| SG171997A1 (en) * | 2008-12-08 | 2011-07-28 | Soligenix Inc | Topically active steroids for use in radiation and chemotherapeutics injury |
| BR122013006960A2 (pt) | 2009-03-30 | 2019-10-15 | Nestec S.A. | Peptídeo sintético que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado, seu uso e seu método de identificação, bem como kit compreendendo o referido peptídeo |
| CN102286073B (zh) * | 2011-06-27 | 2013-09-11 | 华中科技大学同济医学院附属同济医院 | 一种与牙釉质表面轴向特异性结合的七肽及其应用 |
| US20150148304A1 (en) * | 2013-10-24 | 2015-05-28 | Soligenix, Inc. | Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome |
| KR101742069B1 (ko) * | 2013-10-25 | 2017-05-31 | (주)연우 | 리필이 가능한 압출식 앰플용기 |
-
2014
- 2014-08-11 MX MX2016003092A patent/MX2016003092A/es unknown
- 2014-08-11 SG SG11201601891XA patent/SG11201601891XA/en unknown
- 2014-08-11 PL PL14844276.7T patent/PL3044229T3/pl unknown
- 2014-08-11 US US15/021,889 patent/US9850279B2/en active Active
- 2014-08-11 FI FIEP14844276.7T patent/FI3044229T3/fi active
- 2014-08-11 CA CA2923553A patent/CA2923553C/en active Active
- 2014-08-11 HU HUE14844276A patent/HUE066502T2/hu unknown
- 2014-08-11 AU AU2014318247A patent/AU2014318247B2/en active Active
- 2014-08-11 HR HRP20231652TT patent/HRP20231652T1/hr unknown
- 2014-08-11 RU RU2016110153A patent/RU2668963C2/ru active
- 2014-08-11 KR KR1020217029666A patent/KR102483333B1/ko active IP Right Grant
- 2014-08-11 MY MYPI2016000451A patent/MY177930A/en unknown
- 2014-08-11 LT LTEPPCT/US2014/050516T patent/LT3044229T/lt unknown
- 2014-08-11 KR KR1020217010249A patent/KR102304906B1/ko active IP Right Grant
- 2014-08-11 KR KR1020167009699A patent/KR20160058845A/ko not_active Application Discontinuation
- 2014-08-11 NZ NZ71853414A patent/NZ718534A/en unknown
- 2014-08-11 BR BR112016005557-8A patent/BR112016005557B1/pt active IP Right Grant
- 2014-08-11 JP JP2016541974A patent/JP6645968B2/ja active Active
- 2014-08-11 ES ES14844276T patent/ES2965906T3/es active Active
- 2014-08-11 NZ NZ756128A patent/NZ756128A/en unknown
- 2014-08-11 WO PCT/US2014/050516 patent/WO2015038264A1/en active Application Filing
- 2014-08-11 DK DK14844276.7T patent/DK3044229T3/da active
- 2014-08-11 EP EP14844276.7A patent/EP3044229B1/en active Active
- 2014-08-11 PT PT148442767T patent/PT3044229T/pt unknown
- 2014-08-11 CN CN201480062073.1A patent/CN105722852B/zh active Active
-
2016
- 2016-03-13 IL IL244573A patent/IL244573B/en active IP Right Grant
- 2016-03-22 ZA ZA2016/01967A patent/ZA201601967B/en unknown
- 2016-08-24 HK HK16110061.5A patent/HK1221960A1/zh unknown
-
2017
- 2017-12-20 US US15/848,746 patent/US10253068B2/en active Active
-
2018
- 2018-08-13 AU AU2018214160A patent/AU2018214160B2/en active Active
-
2019
- 2019-04-11 JP JP2019075940A patent/JP2019142910A/ja active Pending
-
2020
- 2020-05-25 AU AU2020203410A patent/AU2020203410A1/en not_active Abandoned
-
2022
- 2022-08-19 ZA ZA2022/09308A patent/ZA202209308B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231652T1 (hr) | Peptidi za primjenu u liječenju oralnog mukozitisa | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| IL262805B1 (en) | CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death | |
| HRP20190500T1 (hr) | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina | |
| FI3482765T3 (fi) | Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| JP2013520405A5 (hr) | ||
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| JP2015527402A5 (hr) | ||
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| JP2015518818A5 (hr) | ||
| JP2013537195A5 (ja) | 疾患を治療するための医薬品及び同医薬品を含むキット | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| JP2014050390A5 (hr) | ||
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| HRP20211197T1 (hr) | Rekombinantni glikoproteini i njihova uporaba | |
| JP2017530130A5 (hr) | ||
| JP2016517421A5 (hr) | ||
| HRP20230387T1 (hr) | Farmaceutski pripravci koji sadrže anti-beta amiloidna antitijela | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| HRP20231587T1 (hr) | Kronično noćno doziranje lasmiditana radi sprječavanja migrene | |
| UY31826A (es) | Compuesto peptídico y su uso | |
| JP2013542196A5 (hr) | ||
| AR108676A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant |